scholarly journals Effects of a Herbal Medicine, Yukgunja-Tang, on Functional Dyspepsia Patients Classified by 3-Dimensional Facial Measurement: A Study Protocol for Placebo-Controlled, Double-Blind, Randomized Trial

2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Juyeon Kim ◽  
Jae-Woo Park ◽  
Seok-Jae Ko ◽  
Soo-Hyung Jeon ◽  
Jong-Won Kim ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Clinical Practice ◽  
Herbal Medicine ◽  
Functional Dyspepsia ◽  
Symptom Scale ◽  
Double Blind ◽  
Korean Medicine ◽  
3 Dimensional ◽  
Objective Evidence

Introduction. Functional dyspepsia (FD), a common upper gastrointestinal disease, is difficult to manage because of the limitations of current conventional treatments. Yukgunja-tang (YGJT) is widely used to treat FD in clinical practice in Korea, Japan, and China. However, YGJT significantly improves few symptoms of FD. In Korean medicine, FD is a well-known functional gastric disease that shows difference in the effect of herbal medicine depending on constitution or type of Korean medicine diagnosis. This study aims to investigate the efficacy of YGJT on FD patients classified by 3-dimensional facial measurement using a 3-dimensional facial shape diagnostic system (3-FSDS).Methods. A placebo-controlled, double-blind, randomized, two-center trial will be performed to evaluate the efficacy of YGJT on FD patients. Eligible subjects will be initially classified as two types by 3-dimensional facial measurement using the 3-FSDS. Ninety-six subjects (48 subjects per each type) will be enrolled. These subjects will be randomly allocated into treatment or control groups in a 2 : 1 ratio. YGJT or placebo will be administered to each group during the 8-week treatment period. The primary outcome is total dyspepsia symptom scale, and the secondary outcomes include single dyspepsia symptom scale, proportion of responders with adequate symptom relief, visual analog scale, Nepean dyspepsia index-Korean version, functional dyspepsia-related quality of life, and spleen qi deficiency questionnaire.Discussion. This is the first randomized controlled trial to assess the efficacy of the YGJT on FD patients classified by 3-dimensional facial measurement. We will compare the treatment effect of the YGJT on FD patients classified as two types using the 3-FSDS. The results of this trial will help the FD patients improve the symptoms and quality of life effectively and provide objective evidence for prescribing the YGJT to FD patients in clinical practice.Trial Registration. This trial is registered with Clinical Research Information Service Identifier:KCT0001920, 15 May, 2016.

scholarly journals An Herbal Medicine, Yukgunja-Tang is more Effective in a Type of Functional Dyspepsia Categorized by Facial Shape Diagnosis: A Placebo-Controlled, Double-Blind, Randomized Trial

2018 ◽  
Vol 2018 ◽  
pp. 1-11 ◽  
Author(s):  
Seok-Jae Ko ◽  
Jae-Woo Park ◽  
Jae-hyung Lee ◽  
Jung-eun Lee ◽  
Na-yeon Ha ◽  
...  
Keyword(s):  
Herbal Medicine ◽  
Functional Dyspepsia ◽  
Three Dimensional ◽  
Gastrointestinal Symptoms ◽  
Diagnostic System ◽  
Gastrointestinal Disorder ◽  
Symptom Scale ◽  
Double Blind ◽  
Facial Shape ◽  
Superior Effect

Introduction. Functional dyspepsia (FD) is a functional gastrointestinal disorder characterized by persistent upper dyspeptic symptoms without organic lesions. There is no standard therapy for FD. Yukgunja-tang (YGJT) is an herbal medicine used for treating upper gastrointestinal symptoms in Asia. Studies on the effect of YGJT on FD have been conducted. However, the results were inconsistent. In Hyungsang medicine, traditional Korean medicine, FD patients are classified into bladder body (BB) or gallbladder body (GB) subtypes by the shape and angle of their faces. Each subtype may have different characteristics, physiology, and pathology of the same disease. YGJT is more effective for patients with BB subtype. The three-dimensional facial shape diagnostic system (3-FSDS) was shown to be effective in diagnosing BB or GB subtypes. This study aimed to investigate the effect of YGJT on FD patients classified using the 3-FSDS. Materials and Methods. The current study was a placebo-controlled, double-blinded, randomized, two-center trial. Eligible patients were diagnosed with either BB or GB FD subtype using the 3-FSDS. Ninety-six participants (48 BB and 48 GB subtypes) were randomly allocated to treatment or control groups in a 2:1 ratio. YGJT or placebo was administered for eight weeks. The primary outcome was assessed using the total dyspepsia symptom scale (TDS), while the secondary outcomes were assessed using the single dyspepsia symptom scale (SDS), proportion of responders, visual analog scale, Nepean dyspepsia index, functional dyspepsia-related quality of life, and spleen qi deficiency questionnaire. Results and Discussion. The result of TDS showed the superior effect of YGJT on BB over GB subtype. The subgroup analysis of TDS and SDS scores showed the superior effect of YGJT over placebo. Other outcome variables did not show any significant differences between groups. Conclusion. YGJT may be considered for FD patients diagnosed with BB subtype using 3-FSDS.

scholarly journals Chinese herbal formula Xuefu Zhuyu for primary dysmenorrhea patients (CheruPDYS): a study protocol for a randomized placebo-controlled trial

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Geng Li ◽  
Zhe Zhang ◽  
Li Zhou ◽  
Shaojun Liao ◽  
Jing Sun ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Pain Intensity ◽  
Controlled Trial ◽  
Primary Dysmenorrhea ◽  
Efficacy And Safety ◽  
Clinical Trial Registry ◽  
Symptom Scale ◽  
Double Blind ◽  
Chinese Herbal

Abstract Background Epidemiological studies have shown that young women often suffer from primary dysmenorrhea (PD) which is a common cause that affects their routine work and quality of life. Chinese herbal medicine has been widely used for PD in China. A systematic review found that Xuefu Zhuyu (XFZY) has a promising effect on PD management, yet there is a dearth of high-quality evidence in support of this claim. We want to conduct a randomized controlled trial to evaluate the efficacy and safety of XFZY for PD patients. Methods This is a protocol for a multicenter, randomized, placebo-controlled trial. A total of 248 participants with PD will be recruited at 6 centers and randomized into two groups—a herbal treatment group and a placebo group. The participants will receive either XFZY or placebo, three times per day, for 3 menstrual cycles, with a 12-week follow-up. The primary outcome will be the mean change in pain intensity as measured by VAS, while the change in menstrual pain duration, the change in peak pain intensity as measured by VAS, the Cox Menstrual Symptom Scale (CMSS), quality of life EQ-5D-5L, cumulative painkiller consumption, and health economics will be included as secondary outcomes. Adverse events will also be reported. Discussion This protocol describes a multicenter, double-blind, randomized, placebo-controlled trial that investigates the efficacy and safety of XFZY for primary dysmenorrhea. Validated evaluation tools will assess dysmenorrhea severity. We believe that this research will provide important evidence regarding the use of XFZY to treat dysmenorrhea. Trial registration Chinese Clinical Trial Registry ChiCTR1900026819. Registered on 23 October 2019

scholarly journals An Extract ofGlycyrrhiza glabra(GutGard) Alleviates Symptoms of Functional Dyspepsia: A Randomized, Double-Blind, Placebo-Controlled Study

2012 ◽  
Vol 2012 ◽  
pp. 1-9 ◽  
Author(s):  
Kadur Ramamurthy Raveendra ◽  
Jayachandra ◽  
Venkatappa Srinivasa ◽  
Kadur Raveendra Sushma ◽  
Joseph Joshua Allan ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Functional Dyspepsia ◽  
Global Assessment ◽  
Short Form ◽  
Secondary Outcome ◽  
Controlled Study ◽  
Secondary Outcome Measure ◽  
Double Blind ◽  
Double Blind Placebo

A randomized, double-blind, placebo-controlled study was conducted to evaluate the efficacy of GutGard, an extract ofGlycyrrhiza glabra, in patients with functional dyspepsia. The primary outcome variables of the study were the change in the severity symptoms and the global assessment of efficacy. The quality of life was evaluated as a secondary outcome measure. The patients received either placebo or GutGard (75 mg twice daily) for 30 days. Efficacy was evaluated in terms of change in the severity of symptoms (as measured by 7-point Likert scale), the global assessment of efficacy, and the assessment of quality of life using the short-form Nepean Dyspepsia Index. In comparison with placebo, GutGard showed a significant decrease (P≤.05) in total symptom scores on day 15 and day 30, respectively. Similarly, GutGard showed marked improvement in the global assessment of efficacy in comparison to the placebo. The GutGard group also showed a significant decrease (P≤.05) in the Nepean dyspepsia index on day 15 and 30, respectively, when compared to placebo. GutGard was generally found to be safe and well-tolerated by all patients. GutGard has shown significant efficacy in the management of functional dyspepsia.

scholarly journals The management of functional dyspepsia in clinical practice: what lessons can be learnt from recent literature?

F1000Research ◽  
2017 ◽  
Vol 6 ◽  
pp. 1778 ◽  
Author(s):  
Maura Corsetti ◽  
Mark Fox
Keyword(s):  
Quality Of Life ◽  
Clinical Practice ◽  
Functional Dyspepsia ◽  
Clinical Management ◽  
Recent Literature ◽  
Gastrointestinal Disorder ◽  
Healthcare Services ◽  
Functional Gastrointestinal Disorder ◽  
Cost Burden

Functional dyspepsia is a prevalent functional gastrointestinal disorder that can significantly erode the quality of life of sufferers and places a major cost burden on healthcare services. In this article, we review the recent literature, selecting the information we consider relevant since it has changed our clinical management of patients with functional dyspepsia.

scholarly journals A Case Report on Sojaganggi-tang Treatment for a Patient with Asthma

2021 ◽  
Vol 42 (5) ◽  
pp. 1109-1117
Author(s):  
Hye-mi Jo ◽  
Bong-hun Kil ◽  
Eun-chang Lee ◽  
Hye-soo Youn ◽  
Dong-won Kim ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Case Report ◽  
Herbal Medicine ◽  
Medical Treatment ◽  
Life Questionnaire ◽  
Borg Scale ◽  
Traditional Korean Medicine ◽  
Korean Medicine ◽  
Quality Of Life Questionnaire

Objectives: This study aimed to describe the effects of traditional Korean medical treatment on a patient with asthma.Methods: The patient (female, 88) was treated with herbal medicine (Sojaganggi-tang), acupuncture, and moxibustion. The effects of these treatments were evaluated using the Modified Borg Scale (MBS) and Quality of Life Questionnaire for Adult Korean Asthmatics (QLQAKA).Results: Following treatment, the MBS score decreased from 7 to 4, and the QLQAKA score increased from 45 to 57.Conclusion: The results suggest that traditional Korean medicine can effectively treat patients with asthma.

scholarly journals The Effects ofBanha-sasim-tangon Dyspeptic Symptoms and Gastric Motility in Cases of Functional Dyspepsia: A Randomized, Double-Blind, Placebo-Controlled, and Two-Center Trial

2013 ◽  
Vol 2013 ◽  
pp. 1-10 ◽  
Author(s):  
Jae-Woo Park ◽  
Seok-Jae Ko ◽  
Gajin Han ◽  
Inkwon Yeo ◽  
Bongha Ryu ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Functional Dyspepsia ◽  
Gastric Motility ◽  
Slow Waves ◽  
Double Blind ◽  
Early Satiety ◽  
Gastric Slow Waves ◽  
Quality Of Life Scale ◽  
Dyspeptic Symptoms

Introduction. Functional dyspepsia (FD) is highly prevalent, and no standard treatments exist for this condition. Herbal prescriptions are widely used to treat FD. In traditional Korean medicine,Banha-sasim-tang(BST) is a famous herbal prescription for dyspepsia. This study aimed to evaluate the efficacy of BST and to examine the relationship between gastric slow waves and dyspeptic symptoms.Materials and Methods. In total, 100 FD patients were recruited; BST or placebo was administered for 6 weeks. The gastrointestinal symptom scale, FD-related quality of life scale, and frequency or power variables regarding gastric slow waves were measured at 0, 6, and 14 weeks.Results. There were no significant differences in the overall dyspeptic symptoms or quality of life between the BST and placebo groups. However, early satiety was significantly improved in the BST group (P=0.009, at 6 weeks by intention-to-treat analysis). Abnormal gastric dysrhythmias and power ratios were also significantly improved by BST.Conclusion. BST had no significant effects on FD. However, early satiety appeared to improve after BST administration. Electrogastrography may be a useful technique for assessing changes in gastric motility dysfunction after interventions for FD. Further investigation focused on specific symptoms or subtypes of FD is required.

Sign in / Sign up

Export Citation Format

Share Document